Insightful Science Joins Forces with Dotmatics to Form a Leading Cloud-First Scientific R&D Company
PR88609
BISHOP'S STORTFORD, United Kingdom and SAN DIEGO, March 22, 2021 /PRNewswire=KYODO JBN/ --
- Combined company will generate well over $100 million of ARR and signals a
significant transformation in the future of software and data management in
research labs.
- Enabling over one million scientists to improve research and lab efficiency.
- Facilitating rapid data access and exchange between scientists around the
world, ultimately giving customers a competitive edge.
Insightful Science (
), a leading software provider serving the global life sciences community,
announced today that it has entered into a transaction to acquire Dotmatics (
), an industry leading cloud-based scientific R&D data management platform.
By integrating Insightful Science's software applications into Dotmatics
cloud-first enterprise data management solution, the company will provide an
end-to-end scientific research platform. This combination further improves
laboratory efficiency and accelerates the pace of scientific innovation by
facilitating more rapid data access, analysis and exchange between scientists
around the world.
Insightful Science is a software company with purpose-built data analysis and
bioinformatics applications for life sciences. The company portfolio serves a
diverse set of one million scientists in academic, corporate, and government
institutions around the world. Examples of products within the Insightful
Science portfolio (
) include GraphPad Prism (
), Geneious (
) DNA data analysis solutions, SnapGene (
), and other leading R&D solutions.
Dotmatics is an enterprise scientific informatics SaaS provider that is driving
the digitalization of laboratory data workflows for scientific discovery and
innovation across the life sciences, chemicals and materials industries.
"This announcement signals a significant transformation in the future of
software and data management in research labs," said Thomas Swalla, CEO of
Insightful Science. "Together our complementary businesses create an end-to-end
cloud-first scientific research platform that stands apart in our collective
ability to support data-driven research. We are beyond enthusiastic about the
impact we can have on increasing the speed of scientific innovation, and
ultimately helping to make the world a healthier, cleaner, and better place to
live."
"The number one challenge for pharmaceutical, biotech and chemical innovation
companies today is how to manage the enormous volume — and promise — of data
generated in labs," said Dr Steve Gallagher, Co-founder and CEO of Dotmatics.
"This combination allows us to expand investments in our Dotmatics platform and
strengthen our brand as a leading enterprise informatics solution provider. We
will bring Insightful Science's leading biologics applications to our
customers, further accelerating their discovery processes. In addition, we have
the opportunity to bring the Dotmatics cloud and collaboration capabilities to
the diverse community of over one million scientists already using Insightful
Science tools."
Digital Transformation to Chart the Course for the Lab of the Future
Scientific research and innovation R&D is in the midst of a pivotal
transformation. Scientific knowledge and growth in pharmaceutical drug
discovery and chemicals and materials innovation is increasing at a faster pace
than ever before. The research process has been transformed from transactional
and process driven, to data driven. As a result, scientists require
increasingly powerful and integrated informatics tools to analyze ever-more
diverse sets of data; and laboratories and companies need better workflow and
data management solutions to help scientists harness the power of these
insights. Companies that own the cleanest, best annotated data to power their
AI analytics and decision making, will be the best placed to be successful in
this new paradigm.
Transaction Details
Insightful Science is a privately held portfolio company of Insight Partners (
), the leading global venture capital and private equity firm investing in
high-growth technology and software ScaleUp companies.
"The combination of these two entities brings an exciting new solution to
market," said Jeff Lieberman, Managing Director at Insight Partners. "This
announcement and collaboration is a significant opportunity for the life
sciences, chemicals and materials industries. We are incredibly optimistic
about the future of the company and its clear path to doing for life sciences
and chemical innovation what other market-leading platforms have done in
engineering, design, and later-stage drug development."
Alastair Hill, Co-founder and CIO of Dotmatics added, "Since initial growth
equity investment by Scottish Equity Partners (SEP), we have been supported to
make incredible progress in scaling our business and driving product
innovation. We would like to thank them for their support as we enter the next
exciting stage in Dotmatics' development, and Jefferies for advising on the
transaction."
Evercore served as financial advisor and Willkie Farr & Gallagher LLP served as
legal advisor to Insightful Science on the transaction. Jefferies International
Ltd served as advisor to Dotmatics.
Scottish Equity Partners (
) (SEP) is a leading European growth equity firm, investing in enterprise and
consumer-focused software and technology companies.
Keith Davidson, Partner at SEP said, "We are pleased to have helped Dotmatics
grow into a leading cloud-first scientific R&D data platform. We are excited by
the opportunity that lies ahead for the team and wish them every success in the
future."
Subject to the attainment of regulatory clearances, the transaction is expected
to close in Q2 of 2021. Until closing, the companies will continue to operate
independently.
For more information, visit www.dotmatics.com and www.insightfulscience.com.
About Insightful Science
Insightful Science is a life sciences software company that digitally connects
researchers to their ideas and data, advancing the discovery process. From
developing new personalized and preventive patient treatment solutions to
reversing climate change — more than two million researchers at leading life
science and biopharma enterprises trust Insightful Science products to make the
world a healthier, cleaner, and better place to live. Products within the
Insightful Science portfolio were built by prominent scientists, and include
GraphPad Prism, Geneious Prime and Geneious Biologics, SnapGene, nQuery,
Cytapex, and more.
Visit www.insightfulscience.com for more information about the company and its
products.
About Dotmatics Ltd. www.dotmatics.com
Dotmatics is a scientific informatics software and services company that is
driving the automation of laboratory workflows for discovery and innovation
research - accelerating the journey towards full digitalization and the Lab of
the Future.
With a mission to give scientists access to all of their data, all of the time,
Dotmatics provides a portfolio of tools for fully automated, end-to-end
workflows including data acquisition, knowledge management, data storage, and
enterprise querying and reporting. Through these comprehensive solutions, the
Company is helping its customers to increase lab efficiency and make better
informed decisions driven by all data.
Dotmatics' customers include many of the world's leading pharmaceutical,
biotechnology, contract research, chemicals and materials companies. Insight
into the challenges faced by these organizations enables Dotmatics to focus on
delivering versatile and intuitive products and services that have potential to
turn around the productivity deficit in research and accelerate development of
novel drug candidates or products.
Dotmatics was founded in 2005 by two scientists from Merck Pharmaceuticals
(MSD). Since then it has built a strong and profitable business with an expert
team of over 300 scientists, software developers and engineers, and project
managers. The Company is headquartered in the UK with offices in USA, Korea and
Japan.
SOURCE: Insightful Science
CONTACT: Sarah Jeffery, Zyme Communications, E:
sarah.jeffery@zymecommunications.com, T: +44 (0)7771 730 919
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
